The Effectiveness of Minimally Invasive Techniques in the Treatment of Patellar Tendinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials by López-Royo M.P. et al.
Research Article
The Effectiveness of Minimally Invasive Techniques in the
Treatment of Patellar Tendinopathy: A Systematic Review and
Meta-Analysis of Randomized Controlled Trials
M. P. López-Royo,1,2 M. Ortiz-Lucas ,1 E. M. Gómez-Trullén,2 and P. Herrero1
1iPhysio Reaserch Group, Universidad San Jorge, Campus Universitario, Autov. A23, Km 299, Villanueva de Gállego,
Zaragoza 50830, Spain
2Universidad de Zaragoza, Facultad de Ciencias de la Salud, Dpto. de Fisiatŕıa y Enfermeŕıa, C/Domingo Miral s/n,
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-e aim was to determine the effectiveness of minimally invasive techniques (MIT) in patients with patellar tendinopathy.
Database searches were performed for randomized controlled trials (RCTs) in electronic databases (WOS, Cochrane Central,
SportDiscus, and Medline via PubMed and PEDro). -e inclusion criteria used were published in English or Spanish and
involving adults with patellar tendinopathy (pain on the inferior pole of the patella for a minimum of 3 months), with at least one
group receiving MIT. -e quality of the relevant RCTs was evaluated using the PEDro scale. -e primary outcome was
functionality using the VISA-p questionnaire. Secondary outcome was focused on pain. A total of 1164 studies were screened for
possible inclusion in our systematic review. Finally, 10 RCTs were included with a total of 326 individuals. Five RCTs were
included in the meta-analysis. -e quality assessment revealed that all the studies included were considered to possess high
methodological quality. All studies analyzing MIT such as platelet-rich plasma (PRP), dry needling, or skin-derived tenocyte-like
cells, when combined with exercise, proved to be effective for patellar tendinopathy. Moreover, the PRP technique with doses
greater than 4mL together and combined with an exercise program lasting over 6 weeks obtained better results in functionality
and pain than other treatments in the short term. However, in the long term, dry needling and skin-derived tenocyte-like cells are
more effective than PRP. Although the infiltration of drugs was effective at posttreatment, these improvements were not
maintained over time and may have secondary effects. Although there are no RCTs analyzing the effectiveness of MIT like
percutaneous needle electrolysis, there has been an increasing number of publications achieving excellent results in the last years.
However, it is necessary to develop RCTs analyzing not only the effect but also comparing the effectiveness between different MIT
such as dry needling and percutaneous needle electrolysis.
1. Introduction
Patellar tendinopathy (PT) is a degenerative disease of the
patellar tendon, in which the patient complains of pain in the
inferior pole of the patella. Also, a disturbed collagen dis-
tribution, changes in vascularity and cellularity, increased
thickness of tendon, and incompletely healed tendon
microruptures are common changes observed in patients with
this pathology [1–3]. -e major cause of this injury is overuse
during activities that involve jumping, running, and rapid
changes of direction, which are very common movements in
sports such a basketball and volleyball. Specifically, in non-
professional athletes, the prevalence varies between 2.5% in
soccer players and 14.4% in volleyball players. In contrast, in
both elite sports, 40–50% of professional athletes are affected
[4–6]. -e diagnosis of PT is typically based on medical
history and clinical findings [7]. Imaging techniques such as
Color Doppler sonography (CD) and magnetic resonance
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imaging (MRI) are valuable tools to confirm the diagnosis and
provide guidance for treatment [8].
Conventional treatments such as eccentric exercise (EE)
programs for the quadriceps tendon, as a part of standard
treatment, has demonstrated to have positive results, to the
point that many authors have defended this technique as the
gold standard for the treatment of tendinopathies [9–12]. A
recent systematic review reported that the best exercise for
improving knee function and reducing pain in the long term
is based on EE and heavy slow resistance exercises (HSR)
[13]. In addition, recent research has focused on minimally
invasive techniques (MIT) using needles, with high expec-
tations of success. -ese techniques seek a rapid regenera-
tion of the injured tendon and the relief of chronic pain
[4, 8, 14–16]. -eir effect is based on stimulating the cellular
activity and the production of collagen, as well as influencing
the biomechanics of tendons to obtain restructuration of the
matrix.
It can be classified according to whether they inject
any substances or not. Regarding techniques that do not
infiltrate any substances, good clinical results are being
reported with dry needling (DN) [17] and percutaneous
needle electrolysis (PNE) [4, 18–20], which adds the effect
of the galvanic current to the mechanical effect of the
needle. PNE combined with EE programs offer excellent
results in terms of the clinical and functional improve-
ment of the patellar tendon in the short-term and a rapid
return to the previous level of activity [4, 18]. Concerning
techniques based on the infiltration of substances, it is
possible to differentiate between pharmacological or
nonpharmacological agents. -e most used technique is
platelet-rich plasma (PRP) [21–23]. Literature reviews
carried out based on the application of the PRP technique
on other tendons have concluded that there are no sig-
nificant differences between PRP and DN or placebo at
the 6-months follow-up, although it seems that there may
be small differences depending on the injured tendon
[24]. Moreover, some reviews and meta-analysis have
analyzed the effect of PRP in PT versus other techniques,
regardless of whether they are conservative or invasive
treatments, finding that PRP seems to be a more effective
treatment in the long term than other treatments, such as
extracorporeal shockwave therapy (ESWT) [15, 25, 26].
However, when compared to other invasive treatments
such as cell therapy or DN, the results for PRP are worse
regarding functionality in the long term, whereas these
other techniques have a promising future for this pa-
thology [27, 28]. Most studies conclude that more studies,
specifically for randomized controlled trials (RCTs), are
necessary to make accurate conclusions with scientific
rigor, as most of the included studies reviewed are of low
scientific quality.
A variety of MIT are being used in clinics for the
treatment of PT, either used alone or as a complement to
other conservative treatments. However, evidence-based
therapies are limited, and there is no consensus regarding
which of these is the most effective. -e variability of the
types of studies, together with the low quality of the same,
lead us to consider the need for a review and meta-
analysis of high-quality RCT on MIT for the treatment of
PT.
-us, our primary aim was to systematically review the
effectiveness of MIT for functionality and pain of the PT in
humans. Where possible, meta-analysis of outcome data on
pain and function was performed.
2. Materials and Methods
A systematic review and meta-analysis were performed
according to the Preferred Reporting Items for Systematic
Review and Meta-Analysis (PRISMA) [29]. -e review was
registered in the international PROSPERO database
(CRD42015025801). -e software used to assemble all the
papers included in this review is EndNote X7 v17.0.1.
2.1. Data Sources and Searches. We conducted a systematic
literature search in Web of Science, Cochrane Central,
SportDiscus, and Medline via PubMed and PEDro. -e
database search was conducted by two reviewers (MPLR and
EMGT) in January 2018 with the final search conducted in
September 2019, using the following search terms: patellar
ten∗, patellar ligament, jumper’s knee, chronic patellar ten∗,
dry need∗, intratissue percutaneous electrolysis, acupunc-
ture, electroacupuncture, mesotherapy, injection,
injectable∗, puncture, and infiltrate∗. Search strategy for
Medline is described in detail in Appendix 1.
Two independent reviewers (MPLR and EMGT)
screened the titles and/or abstracts and full texts according
to the stated inclusion criteria. Discrepancies were discussed
at a consensus meeting, and the opinion of a third inde-
pendent reviewer (MOL) was sought if agreement could not
be achieved. Reviewers were not blinded to information
regarding the authors, journal of origin, or outcomes for
each paper reviewed.
2.2. Study Selection. -e inclusion criteria were as follows:
(a) RCT; (b) English or Spanish; (c) involving adults; (d)
with a diagnosis of chronic patellar disease (minimum of 3
months of pain in the inferior pole of the patella); and (e) at
least one group receiving MIT. We excluded articles in
which the sample was under 18 years old, non-RCTs
(quasiexperimental trials, case series, and observational
studies), and those in which subjects had received a previous
surgical intervention.
In studies with more treatment groups in which patients
underwent different procedures, each treatment group was
analyzed independently according to the treatment applied
and always compared with the group receiving MIT.
2.3. Data Extraction. -e primary outcome evaluated was
functionality using the Victorian Institute of Sport Assess-
ment of Patellar Questionnaire (VISA-p) [30]. Secondary
outcome measures focused on pain.
A standardized electronic data extraction form was
developed to obtain key information relevant to this review.
Data extraction for each article was performed by two
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authors (MPLR and EMGT), with a third reviewer (MOL)
solving potential discrepancies, and including the following:
(1) sample characteristics (sample age and sample sex); (2)
methodological characteristics (study design, number of
groups, associated interventions, time of measurements, and
assessment tools); (3) main results; and (4) conclusions.
Finally, ameta-analysis was performed grouping the RCTs
according to the technique used. Means, standard deviation
(SD), and sample sizes for pain and function were extracted
for each group at short-term and medium/long-term follow-
up. When data were not extractable or expressed in other
form instead of mean and SD, a total of three attempts were
made contacting with the corresponding author to request the
information by e-mail, and in case of not getting an answer of
the study data, were not used for themeta-analysis. To analyze
the benefit of this treatment, studies without pre- and
postintervention data were excluded.
2.4. Risk of Bias Assessment. -e quality of the relevant RCTs
was evaluated using the PEDro scale. Eleven PEDro criteria
were used to evaluate the quality of the retrieved studies. Each
satisfied item (except for item 1, which, unlike other scale
items, pertains to external validity) contributes one point to
the total PEDro score (range 0–10 points). Each criterion was
assessed with the alternatives ‘‘Yes’’ (1 point) or ‘‘No” (0
points). Items 2–9 assess internal validity, and the last two
items (10 and 11) reveal whether the statistical information
presented in the study is enough to perform a correct in-
terpretation of the outcomes. Articles fulfilling at least 6/10
positive criteria were considered to be of “good quality,”
studies with 4-5/10 positive criteria were considered to be
“average quality,” and articles with less than 4 points were
considered “poor quality” [31]. Two reviewers (MPLR and
EMGT) separately evaluated the quality of the studies using
the PEDro scale, and when they could not reach agreement, a
third independent reviewer was consulted.
2.5. Statistical Analysis. -e random effects model was used
for all meta-analyses. -e VISA-p score and visual analog
scale (VAS) mean differences and SD for each group (be-
tween pre and posttreatment and between pretreatment and
the follow up) were collected for this purpose. Heterogeneity
between studies was assessed using the Cochran’s Q test, and
the I2 index was used to quantify the amount of heteroge-
neity, with a value greater than 50% indicating substantial
heterogeneity [32, 33]. Additional intragroup meta-analyses
of each treatment differences of means were performed to
explain the heterogeneity found. Also, subgroup analyses
were performed according to dose (≤ or >4mL), amount of
exercise (≤ or >6 weeks), and basal VISA-p score (< or ≥48).
Prior to this, scatter plots of possible factors of heterogeneity
were drawn to detect suitable variables for subgroup analyses
and their cut off values.
3. Results
3.1. Characteristics of Included Trials. A total of 1164 studies
were screened for possible inclusion in this systematic
review; 10 RCTs met our inclusion criteria and included in
the review (Figure 1).
All the articles included in the present review involved
326 individuals, most of whom were athletes practicing
various sports and aged between 18 and 55 years. Func-
tionality with VISA-p was assessed in eight studies
[8, 21, 23, 34–38], and pain was evaluated using a numeric
scale in all studies except one [38]. -e main features of
these studies are summarized in Table 1. -e quality as-
sessment revealed that all the studies included were con-
sidered to be of high methodological quality (≥6 points
about 10) (Appendix 2).
4. Review
A heterogeneity of results was found after performing the
systematic review. On the one hand, MIT that do not in-
filtrate any substances such as DN or PNE showed a high
increase of studies in the last years, although the studies
published are still of low quality except for the one published
by Dragoo et al. [21]. However, there was a protocol pub-
lished by Lopez-Royo et al [41] analyzing the additional
effects of both DN and PNE over EE whose results have not
published yet, but that will increase the knowledge in this
field. On the other hand, other therapies including the in-
filtration of substances, such as PRP therapy, were associated
with a significant improvement in functionality and pain at
posttreatment [21, 34–37] and at follow-up measurements
[21, 35–37] and a significant decrease in hypoechogenicity
and tear size at 6 months [37] in patients with PT, with no
significant differences between one or two PRP injections.
In the systematic review, we found studies comparing
different interventions, such as a study that compared PRP
with ESWT, showing that the effectiveness of two injections
of PRP was superior for pain and functionality measure-
ments at posttreatment and at follow-up and for pain only at
follow-up [35]. In other study, that compared PRP with DN
therapy, controversial results were observed, as, in the short
term (3 months), PRP obtained better results on pain and
functionality compared to DN, whereas at 6months, DNwas
more effective than PRP for functionality [21]. In this study,
when comparing subjects at baseline, DN was more effective
than PRP on levels of pain and function also at 6 months.
Moreover, other RCTs have reported PRP as being less ef-
fective than other therapies [34, 37], like the study com-
paring PRP with tenocyte-like cell treatment at 6 months
[37], with the latter showing improved effectiveness for
functionality, pain, tendon thickness, hypoechogenicity, and
tear size. In other recent study [34], comparing two different
groups of leukocyte-poor PRP (LP-PRP) and leucocyte-rich
PRP (LR-PRP) versus saline injection, 58% of the patients
experienced an improvement of the VISA-p score at post-
treatment regardless of their assigned treatment group. In
this study, no significant differences were found between the
three groups in the short term, failing to demonstrate any
significant benefit of LP-PRP or LR-PRP over saline injec-
tion. Eventually, the effectiveness of the autologous blood
(AB) injections was studied in a recent RCT [38], showing
that both AB and saline groups experienced a significant
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improvement in symptoms, with nonsignificant statistical
differences between groups.
Regarding pharmacological treatments, several studies
[8, 23, 38–40] applied different drug infiltrations protocols,
including steroids and sclerosing agents. A study comparing
steroids with placebo showed an improvement at 6 months
in the steroids group for pain measured with a numeric
rating scale and a decrease of tendon thickness, maintaining
this effect at 6 months [39]. Nevertheless, in a study com-
paring corticosteroid injections (CI) with EE and HSRT, all
groups improved functionality, pain, and tendon thickness
and swelling, with significant differences in favor of the CI
group when compared with the other two exercise groups in
the short term. However, these improvements were main-
tained at 6 months for both exercise groups but not for the
group receiving corticosteroids [23]. Polidocanol was ef-
fective on functionality at 4 months posttreatment in one
study [8]; however, no results were found in VAS mea-
surements either in the short or long term [8, 40]. Fur-
thermore, functional improvements were not maintained at
long-term [8]. In a subsequent study of the same group with
a 44-months follow-up, more than one-third of the group
treated with polidocanol ended up in a surgical intervention
because of the pain they suffered. Willberg et al. [40] in their
study showed that the group receiving arthroscopic treat-
ment found better improvements in pain and satisfaction
compared to baseline as opposed to the cited polidocanol
group at 6 weeks [40]; however, once again, the results were
lost in the follow-up period (2, 6, and 12 months).
4.1. Meta-Analysis. -e only MIT with enough RCTs to
carry out a meta-analysis was PRP. For this reason, we
included all articles with at least one group consisting of PRP
injection treatment. Finally, five RCTs were included in the
meta-analysis (Figure 1).
For the meta-analysis, different cutoff points were
established. Regarding the dose of treatment received,
three RCTs [21, 36, 37] applied doses equal to or greater
than 4mL of PRP, and two RCTs [34,35] employed three
different injections, applying doses less than 4mL. -ese
same subgroups were obtained when comparing the
duration of EE performed by the subjects of the PRP
group. When the dose was bigger than 4mL of PRP, a



























No control group = 48
No humans = 1
No PT = 4
No regenerative treatment = 4
Figure 1: PRISMA flow diagram. PT�patellar tendinopathy; WOS�Web of Science.
4 Evidence-Based Complementary and Alternative Medicine
Table 1: Study characteristics of the included trials.
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Table 1: Continued.







Injections of 1mL of 40mg/
mL methylprednisolone in
0.5mL lidocaine (1%).















and color area at 12wks.
ECC: significant
improvement on VISA-






area at 12wks and on
VISA-p and VAS at
6mo.
HSRTvs. EE vs. CORT:
VISA-p improvement
from baseline to 6mo
was significantly higher
in HSRT and EE than
CORT.
VAS improvement




CORT has good clinical
effects at 3mo but poor
results at 6mo in PT.
HSRT and EE have good
clinical effects at 3 and






3 x 15 repetitions of
eccentric unilateral squats
on a 25° decline board twice




15 repetitions maximum of
3 bilateral exercises: squat,
leg-press, and hack squat
three times a week for
12wks. RM wks 1, 12 RM
wks 2-3, 10 RM wks 4-5, 8









times maximum in 4mo.



















p at 8 and 12mo.
TG vs. CG: more
satisfaction in TG
compared with the CG
at 4mo.
Sclerosing injections with
polidocanol resulted in a
significant improvement
in knee function and
reduced pain measured
with VISA-p in patients





adrenalin) (5mg/mL+ 5 g/






























diameter at 7 days, 21






steroids vs. placebo on
NRS at 6mo.
Ultrasonographically











3 infiltrations (0, 7, and 21
days). Placebo injection
contained 3.5mL of 1%
lidocaine and 0.5mL of
20% intralipid in a 5-mL
syringe
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Table 1: Continued.
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however, when the dose was less than 4mL, the exercise
program lasted 6 weeks or less. Regarding the mean
baseline score of the VISA-p, the following subgroups
were defined: subjects with less than 48 points [21, 34]
and subjects with more than 48 points [34–37].
4.2. Intergroup Differences. -ere was no difference be-
tween groups in the case of the VISA-p after treatment or
at follow-up (Figures 2(a) and 2(b)). However, in those
studies where the dose was greater than 4mL and the
duration of the exercise program was longer than 6 weeks,
treatment with PRP was better than other therapies after
treatment. Surprisingly, the opposite happened in the
follow-up (Figures 3(a) and 3(b)).
Concerning the effectiveness of treatment in the
management of pain measured by VAS, PRP was superior
to other treatments in the case of doses greater than 4mL
and exercise programs of more than 6 weeks duration
after treatment. In the follow-up, there were no differ-
ences between groups in any of the situations (Figures 4(a)
and 4(b)).
4.3. Intragroup Differences for the PRP Group. Concerning
the intragroup analysis of those patients treated with PRP,
treatment was effective both after treatment and during the
follow-up, according to both measurement scales: the VISA-
p (Figures 5(a) and 5(b)) and VAS (Figures 6(a) and 6(b)). In
the case of pain, heterogeneous findings were found;
however, the results of all studies suggest an improvement
after treatment.
5. Discussion
-e main finding of this study was that all studies analyzing
MIT, such as PRP, DN, or cells, when combined with ex-
ercise, were found to be effective for PTat posttreatment and
follow-up. -is systematic review has identified ten RCTs
assessing the effectiveness of MIT in the treatment of PT. A
meta-analysis was conducted with five RCTs that included
PRP injection. It was not possible to perform meta-analysis
with otherMITdue to a lack of data for conducting statistical
analysis. All studies selected in this review had a high-quality
level.
MITcan be divided into two different groups, depending
on whether they inject any substances or not. For the in-
jection of substances, a differentiation can be made between
infiltrating pharmacological agents or nonpharmacological
ones. In our review, all injection therapies with pharma-
cological agents (i.e., steroids, corticosteroids, and polido-
canol) obtained good clinical effects in the short term, even
for the decrease of the tendon diameter [8, 23, 40]; however,
in the long term, results were poor [8]. -ese findings are in
line with the conclusions of previous systematic reviews for
the treatment of other tendon disorders affecting other areas
of the body [42,43]. Furthermore, the role of steroids in the
management of tendinopathy is also controversial, sug-
gesting the relapse of symptoms in the long term [43]. Also,
steroid injections may produce undesirable side effects, such
as tendon rupture, as reported elsewhere [42, 44].
Concerning infiltration with nonpharmacological agents
such as PRP, in this meta-analysis, as reported by several
RCTs [25, 26, 42, 45], PRP was found to be an effective
technique for PT treatment, and these effects were main-
tained in the long term. Nonetheless, these studies conclude
the need to perform further quality RCTs including placebo
treatments to elucidate their true effects. Moreover, this
study has found that other MITsuch as tenocyte-like cells or
DN may have better results in the long term for this pa-
thology. Studies focusing on other tendinopathies, which
compare PRP versus MIT that do not infiltrate substances,
are available. In the case of the rotator cuff tendinopathy,
PRP resulted in better results at 3 and 6months when
compared with DN [46]. Nonetheless, a single study com-
paring PRP with DN in PT [21] showed better short-term
results in the case of PRP but the opposite at 6 months follow
up. -ese differences may be due to the comparison of
different tendons and a different methodology, as the
Table 1: Continued.
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single injection of LR-PRP
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52mL of venous blood was
collected. 15% haematocrit




3.5mL saline +HSRT 3
times/wk during 6wks.
AB, autologous blood; Cells, prepared in laboratory (cells of collagen and plasma); CD, Color Doppler; CG, control group; CORT, peritendinous corti-
costeroid injections; DN, dry needling; EE, eccentric decline squat training; ESWT, extracorporeal shock wave therapy; HSRT, heavy slow resistance training;
IKDC, international knee documentation committee form; LP-PRP, leukocyte poor PRP; LR-PRP, leukocyte rich PRP; M, masculine; mo, months; MRI,
magnetic resonance imaging;N, number; NRS, numeric rating scale; PRP, platelet-rich plasma; PT, patellar tendinopathy; RCT, randomized control trial; SF-
12, Short Form–12; TG, treatment group; US, ultrasound; VAS, visual analog scale; VISA-p, Victorian Institute of Sport Assessment of Patellar; wks, weeks; yr,
years.
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aforementioned studies differ in the number of injections
(1–8) and dosage (6mL versus 3mL of PRP and 10 versus
40–50 needle insertions for DN group) in the PTand rotator
cuff tendinopathy, respectively.
In line with the study by Dragoo et al. [21] and Clarke
et al. [37], in our meta-analysis according to the subgroup
analysis, we can affirm that in doses of less than 4mL of PRP,
there is no difference between groups, and when the dose is
more than 4mL of PRP, in the long term, other treatments
are more effective than PRP. One of such treatments is skin-
derived tenocyte-like cells, which has proven to be effective
for the recovery of other tendinopathies, such as lateral
epicondylitis [47]. -erefore, this appears to be a good
option for the treatment of tendinopathies, although further
studies are required to demonstrate the effectiveness of this
same. According to some studies [16, 36, 45], it seems that
different PRP preparations, timing, and frequency of in-
jections should be considered in future studies as these
factors could, at least in part, explain the differences in the
effectiveness of this technique. A recent meta-analysis
compared the application of one or two PRP injections,
showing that two injections do not show better results than a
single injection [16]. In our meta-analysis, we have gone
further and have tried to clarify not only the number of
D + L pooled WMD = –5.28993 (–13.3291, 2.74921)
Heterogeneity chi-squared = 8.13 (d.f = 4) p = 0.087
I-squared = 50.8%
Test of WMD = 0: z = 1.29 p = 0.197
Weighted mean diff.
–36.4829 0 36.4829
Study _  % weight
 Weighted mean diff.
 (95% CI)
 –5.70 (–15.86, 4.46)Vetrano (2013)  24.4
 –20.80 (–36.48, –5.12)Dragoo (2014)  15.9
 –9.90 (–26.23, 6.43)Kaux (2015)  15.1
 6.00 (–5.29, 17.29)Scoot (2019 LP)  22.4
 –2.00 (–13.40, 9.40)Scoot (2019 LR)  22.2
 –5.29 (–13.33, 2.75)Overall (95% CI)
(a)
D + L pooled WMD = 3.47839 (–6.14014, 13.0969)
Heterogeneity chi-squared = 20.48 (d.f. = 5) p = 0.001
I-squared = 75.6%
Test of WMD = 0: z = 0.71 p = 0.478
Weighted mean diff.
–27.7218 0 27.7218
Study _  % weight
 Weighted mean diff.
 (95% CI)
 11.00 (2.51, 19.49)Clarke (2011)  19.4
 –13.80 (–23.80, –3.80)Vetrano (2013)  18.3
 9.70 (–8.32, 27.72)Dragoo (2014)  12.7
 0.30 (–14.45, 15.05)Kaux (2015)  14.8
 16.00 (4.71, 27.29)Scoot (2019 LP)  17.3
 –1.00 (–12.04, 10.04)Scoot (2019 LR)  17.5
 3.48 (–6.14, 13.10)Overall (95% CI)
(b)
Figure 2: Analysis VISA-p mean differences. (a) Analysis VISA-p prepost mean difference. (b) Analysis of VISA-p pre-follow-up mean
difference.
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>4 mL ≤4 mL
D + L pooled WMD = –15.569 (–26.879, –4.259)
I-squared = 0%
Test of WMD: p = 0.007
D + L pooled WMD = –0.875 (–7.675, 5.925)
I-squared = 14.1%
Test of WMD: p = 0.801
Note: weights are from random effects analysis
.
.




Subtotal (I-squared = 14.1%, p = 0.312)
>4
Scoot (2019 LP)


























>4 mL ≤4 mL
D + L pooled WMD = 8.534 (1.724, 15.344)
I-squared = 0%
Test of WMD: p = 0.014
D + L pooled WMD = 0.247 (–6.774, 17.268)
I-squared = 86.7%
Test of WMD: p = 0.977
Note: weights are from random effects analysis
.
.




































Figure 3: Subgroup analysis VISA-pmean difference. (a) Subgroup analysis VISA-p prepost mean difference. (b) Subgroup analysis VISA-p
pre-follow-up mean difference.
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>4 mL ≤4 mL
D + L pooled WMD = 1.828 (0.670, 2.987)
I-squared = 0%
Test of WMD: p = 0.002
D + L pooled WMD = 0.344 (–1.035, 1.723)
I-squared = 73.6%
Test of WMD: p = 0.625
Note: weights are from random effects analysis
.
.
Overall (I-squared = 66.6%, p = 0.018)
Kaux (2015)
Scoot (2019 LR)






























Note: weights are from random effects analysis
.
.
Overall (I-squared = 83.9%, p = 0.001)
Kaux (2015)
Scoot (2019 LR)






























D + L pooled WMD = 1.600 (–2.124, 5.324)
I-squared = 91.2%
Test of WMD: p = 0.400
D + L pooled WMD = 0.609 (–1.126, 2.34)
I-squared = 82.6%
Test of WMD: p = 0.491
(b)
Figure 4: Subgroup analysis VAS mean difference. (a) Subgroup analysis VAS prepost mean difference. (b) Subgroup analysis VAS pre-
follow-up mean difference.
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infiltrations but also what is the dose producing the vest
results. -us, our study provides novel and valuable in-
formation regarding the PRP technique and what appears to
be the best dose.
In the most recent RCT (2019) [34], aimed at examining
the differences between the concentration of leukocytes
injected in the PRP, a platelet-rich sample was compared
with a platelet-poor sample and a final control group with a
saline solution. -is study revealed that there are no dif-
ferences between the groups neither in the short nor in the
long term. Along these lines, Resteghini et al. [38] compared
the effectiveness of AB versus saline and found no differ-
ences between groups. Finally, this review is in line with a
previous study [21] that reported that PRP was not superior
to placebo or DN at a 6-month follow-up for tendinopathy
treatment. -ese results may support the hypothesis by
Weighted mean diff.
–41.2971 0 41.2971
Study _ % weight
Weighted mean diff.
(95% CI)
 –20.90 (–29.82, –11.98)Vetrano (2013) 38.4
 –25.40 (–41.30, –9.50)Dragoo (2014) 12.1
 –13.90 (–31.94, 4.14)Kaux (2015) 9.4
 –22.00 (–34.44, –9.56)Scoot (2019 LP) 19.7
 –14.00 (–26.23, –1.77)Scoot (2019 LR) 20.4
 –19.60 (–25.12, –14.07)Overall (95% CI)
D + L pooled WMD = –19.595 (–25.122, –14.068)
Heterogeneity chi-squared = 1.92 (d.f = 4) p = 0.750
I-squared = 0.00%
Test of WMD = 0: z = 6.95 p ≤ 0.001
(a)
Study _ % weight
Weighted mean diff.
(95% CI)
D + L pooled WMD = –23.1575 (–29.9637, –16.3513)
Heterogeneity chi-squared = 9.80 (d.f = 5) p = 0.081
I-squared = 49.0%
Test of WMD = 0: z = 6.67 p ≤ 0.001
Weighted mean diff.
–44.3742 0 44.3742
–20.00 (–29.34, –10.66)Clarke (2011) 21.3
–31.40 (–39.64, –23.16)Vetrano (2013) 23.4
–26.80 (–44.37, –9.23)Dragoo (2014) 10.5
–25.10 (–42.12, –8.08)Kaux (2015) 11.0
–26.00 (–37.77, –14.23)Scoot (2019 LP) 17.2
–9.00 (–21.23, 3.23)Scoot (2019 LR) 16.5
–23.16 (–29.96, –16.35)Overall (95% CI)
(b)
Figure 5: Intragroup VISA-p mean difference in the PRP group. (a) Intragroup prepost VISA-p mean difference in the PRP group. (b)
Intragroup pre-follow-up VISA-p mean difference in the PRP group.
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Vetrano [35] who proposed that needling on tissues with
tendinopathy may provide cellular and humoral mediators,
which promote the healing of tissues.
Although there are no RCTanalyzing the effectiveness of
MIT like PNE, there has been an increasing number of
publications achieving excellent results in the last years
[4, 18–20]. However, it is necessary to develop RCTs ana-
lyzing not only the effect but also comparing the effec-
tiveness between different MIT such as DN and PNE.
Fortunately, this review found two high quality protocols
published that aim to compare the effects of PNE and DN in
PT [41] and plantar heel pain [48], although results are not
available yet.
-e studies previously mentioned in this review testing
cell therapy, PRP, DN, and AB [21, 31, 34, 35, 37, 38] were
accompanied by a standardized program of exercise during
treatment, most of themwith EE which is until now, the gold
standard technique for the treatment of this injury.
Study _ % weight
Weighted mean diff.
(95% CI)
D + L pooled WMD = 2.61934 (1.65689, 3.58179)
Heterogeneity chi-squared = 9.87 (d.f. = 4) p = 0.043
I-squared = 59.5%
Test of WMD = 0: z = 5.33 p ≤ 0.001
Weighted mean diff.
–5.24613 0 5.24613
 3.40 (2.36, 4.44)Vetrano (2013)  24.6
 2.40 (0.95, 3.85)Dragoo (2014)  19.3
 3.25 (1.25, 5.25)Kaux (2015)  13.9
 3.20 (1.83, 4.57)Scoot (2019 LP)  20.3
 1.00 (–0.24, 2.24)Scoot (2019 LR)  21.9
 2.62 (1.66, 3.58)Overall (95% CI)
(a)
Study _ % weight
Weighted mean diff.
(95% CI)
D + L pooled WMD = 3.30942 (1.89387, 4.72498)
Heterogeneity chi-squared = 26.24 (d.f. = 4) p ≤ 0.001
I-squared = 84.8%
Test of WMD = 0: z = 4.58 p ≤ 0.001
Weighted mean diff.
–6.46839 0 6.46839
 4.20 (3.13, 5.27)Vetrano (2013)  20.9
 2.40 (1.01, 3.79)Dragoo (2014)  19.3
 5.10 (3.73, 6.47)Kaux (2015)  19.4
 3.80 (2.52, 5.08)Scoot (2019 LP)  19.9
 1.10 (–0.02, 2.22)Scoot (2019 LR)  20.6
 3.31 (1.89, 4.72)Overall (95% CI)
(b)
Figure 6: IntragroupVAS mean difference in the PRP group. (a) Intragroup prepost VAS mean difference in the PRP group. (b) Intragroup
pre-follow-up VAS mean difference in the PRP group.
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However, several studies have shown that HSR is more
effective than EE [23]. Further studies are necessary to re-
define the gold standard of conservative treatment of this
pathology. In the subgroup analysis of functionality and pain
in PRP treatment, RCTs which carried out EE programs over
6 weeks showed greater improvements than those which had
a duration of less than 6 weeks. Further research is needed to
elucidate the ideal type and duration of exercise programs
for the different subtypes of patients with different levels of
functionality.
-e current systematic review and meta-analysis had
several limitations due to the inherent biases of the included
studies. -us, caution should be taken when interpreting the
findings. First, there is a scarcity of RCTs concerning certain
MIT that do not rely on the infiltration of substances (i.e.,
DN or PNE). -is hinders the possibility of performing a
meta-analysis with all the MIT. Second, a standardization of
treatment may be necessary (number of doses, frequency,
and PRP amount).-ird, publication bias may be present, as
only English or Spanish language studies were included, and
only 5 databases were searched; however, in order to de-
crease publication bias, a monthly update of the published
papers on databases were performance.
6. Conclusions
In conclusion, the most important finding of the present
study was that all studies analyzing MIT, such as PRP, DN,
or cells, when combined with exercise, were found to be
effective for PT at posttreatment and follow-up. Moreover,
the PRP technique with doses greater than 4mL together
and combined with an exercise program lasting over 6 weeks
obtained better results in functionality and pain compared to
other treatments in the short-term. However, in the long-
term, DN and skin-derived tenocyte-like cells are more
effective than PRP. In addition, although the infiltration of
drugs was effective at posttreatment, these improvements








ESWT: Extracorporeal shockwave therapy
HSR: Heavy slow resistance exercises
LP-PRP: Leukocyte-poor PRP
LR-PRP: Leucocyte-rich PRP
MIT: Minimally invasive techniques
MRI: Magnetic resonance imaging
PNE: Percutaneous needle electrolysis




RCT: Randomized controlled trial
SD: Standard deviation
VAS: Visual analog scale
VISA-p: Victorian Institute of Sport Assessment of
Patellar Questionnaire
WOS: Web of Science.
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